by Emily Leppien, PharmD, BCPS; Kimberly Mulcahy, PharmD, BCPS, BCPP; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; Eileen Trigoboff, RN, PMHCNS-BC, DNS, DABFN; and Lewis Opler, MD, PhD† Drs.
by Khurshid A. Khurshid, MD, FAASM Dr. Khurshid is Clinical Associate Profressor and Chief of the Neuromodulation and Sleep Disorders Program in the Department of Psychiatry at the University of
by Swapnajeet Sahoo, MD; Susanta Kumar Padhy, MD; Neha Singla, MD; and Aakanksha Singh, MD Drs. Sahoo, Singla, and Singh are Senior Residents and Dr. Padhy is Associate Professor in
by Steven D. Targum, MD; Christopher Murphy, PhD; Jibran Khan, BA; Laura Zumpano, BA; Mark Whitlock, PhD; Arthur A. Simen, MD, PhD; and Brendon Binneman, MD† Drs. Targum and Murphy
This ongoing column explores off-label or emerging treatment options, drug development trends, and theoretical concepts in the field of neuroscience. by Anja Srienc, PhD, MD; Puneet Narang, MD; Simrat Sarai,
by Donna Vanderpool, MBA, JD Ms. Vanderpool is Vice President, Risk Management at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2018;15(3–4):47–51 Funding: No funding was provided for the preparation
